The rapid emergence of acquired resistance significantly limits the effectiveness of EGFR-TKI therapy, while the inability to accurately identify biomarkers in NSCLC patients hampers the development of targeted and effective treatments. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.